Bank of New York Mellon Corp Decreases Position in Bruker Corporation $BRKR

Bank of New York Mellon Corp reduced its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 2.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 899,042 shares of the medical research company’s stock after selling 22,266 shares during the quarter. Bank of New York Mellon Corp owned 0.59% of Bruker worth $37,041,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the period. Allworth Financial LP lifted its holdings in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after buying an additional 364 shares in the last quarter. Spire Wealth Management purchased a new position in Bruker in the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after acquiring an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Up 1.8%

Shares of NASDAQ:BRKR opened at $42.49 on Thursday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64. The company’s fifty day moving average is $35.59 and its two-hundred day moving average is $37.14. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The stock has a market capitalization of $6.46 billion, a price-to-earnings ratio of 81.71, a price-to-earnings-growth ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. Bruker’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is currently -125.00%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BRKR. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. UBS Group increased their target price on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the stock a “hold” rating in a research report on Tuesday, August 5th. Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. Finally, TD Cowen increased their price objective on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday, November 4th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bruker has an average rating of “Hold” and a consensus target price of $48.30.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at $581,016. This represents a 16.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares in the company, valued at $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 27.30% of the stock is owned by corporate insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.